Feline Toxoplasmosis: Neurological Manifestations and Cerebral Involvement

Introduction

Toxoplasmosis is a globally distributed protozoan infection caused by the obligate intracellular apicomplexan parasite Toxoplasma gondii. The domestic cat (Felis catus) serves as the definitive host, supporting the sexual stage of the parasite's life cycle and shedding oocysts into the environment. Although the majority of feline infections are subclinical, neurological involvement constitutes a significant clinical presentation, particularly in immunocompromised animals or in cases of overwhelming primary infection. Cerebral toxoplasmosis arises from the reactivation of latent tissue cysts within the central nervous system (CNS) or from acute dissemination of tachyzoites across the blood-brain barrier. This article reviews the pathogenesis, clinical signs, diagnostic approaches, and therapeutic management of feline toxoplasmosis with specific emphasis on neurological manifestations and cerebral involvement.

Pathogenesis and Cerebral Invasion

Life Cycle and Tissue Cyst Formation

T. gondii exists in three infectious stages: tachyzoites (rapidly replicating), bradyzoites (slowly replicating within tissue cysts), and sporozoites (within oocysts). After oral ingestion of sporulated oocysts (from contaminated food, water, or litter) or tissue cysts (from intermediate hosts such as rodents or birds), the parasite excysts in the feline small intestine and undergoes both enteric enteroepithelial cycles and systemic dissemination.

Tachyzoites disseminate hematogenously and via lymphatic routes. They exhibit a marked tropism for neural and muscular tissues. Within the brain, tachyzoites invade neurons, astrocytes, and microglial cells. The mechanism of invasion involves gliding motility, microneme secretion, and the formation of a parasitophorous vacuole that resists fusion with host lysosomes. Intracellular replication proceeds by endodyogeny until host cell lysis releases progeny to infect adjacent cells.

As the host immune response develops, tachyzoite replication is suppressed by interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha), leading to the conversion into bradyzoites and the formation of quiescent tissue cysts. These cysts persist for the lifetime of the host, predominantly within the cerebral cortex, thalamus, hypothalamus, cerebellum, and brainstem. Rupture of cysts, particularly under conditions of immunosuppression (e.g., concurrent Feline Leukemia Virus or Feline Coronavirus and FIP infection), precipitates reactivation and focal necrotizing encephalitis.

Neuropathology

Histopathological examination of CNS tissue from cats with neurological toxoplasmosis reveals multifocal, asymmetrical areas of necrosis, microgliosis, perivascular cuffing with mononuclear cells, and variable numbers of free tachyzoites and tissue cysts. The necrotic foci are often accompanied by hemorrhage and edema. In chronic cases, granulomatous inflammation and dystrophic mineralization may be observed. Cerebellar involvement can lead to Purkinje cell loss and subsequent ataxia. Meningeal inflammation is less common but may occur secondary to underlying parenchymal necrosis.

The host inflammatory response, while necessary for control of parasitemia, contributes to collateral neural damage through oxidative stress, excitotoxicity, and cytokine-mediated injury. Astrocyte activation and reactive gliosis further disrupt synaptic homeostasis.

Clinical Neurological Manifestations

Neurological signs in cats with cerebral toxoplasmosis are highly variable and depend on the location and extent of lesions. The most frequently reported clinical signs are summarized in Table 1.

Table 1. Common Neurological Signs in Feline Cerebral Toxoplasmosis

Seizures may be the presenting complaint. They can manifest as generalized tonic-clonic activity or as focal motor seizures with facial twitching, limb paddling, or autonomic signs. Status epilepticus has been documented in severe cases. Ataxia is often accompanied by intention tremors or broad-based stance if the cerebellum is affected. Head pressing indicates a forebrain lesion and may be associated with visual impairment or altered mentation.

Behavioral changes such as sudden aggression, excessive vocalization, or disorientation can occur and may be misattributed to idiopathic behavioral disorders if other neurological deficits are subtle. Cranial nerve deficits, including anisocoria, strabismus, and facial hypalgesia, suggest brainstem localization. Involvement of the spinal cord (myelitis) produces paresis, proprioceptive deficits, and spinal hyperesthesia in a minority of cases.

Systemic signs commonly accompany neurological disease: fever, anorexia, lethargy, weight loss, and signs referable to other organ systems such as uveitis (anterior or posterior), pancreatitis, myositis, or pneumonia. Ocular toxoplasmosis presents as chorioretinitis, anterior uveitis, or vitritis, and may be the only extraneural sign.

Diagnostic Challenges and Approaches

Diagnosis of cerebral toxoplasmosis in cats is challenging due to the nonspecific nature of clinical signs, the difficulty in differentiating active disease from latent infection, and the lack of a single definitive antemortem test. A combination of serology, imaging, and molecular testing is recommended.

Serology

Serological detection of anti-T. gondii IgM and IgG antibodies is widely available using commercial ELISA kits and indirect immunofluorescence assays. A positive IgM titer or a rising IgG titer suggests recent or active infection. However, serology alone cannot confirm neurological toxoplasmosis because many clinically normal cats are seropositive for IgG from prior exposure. Furthermore, immunosuppressed cats may have low or undetectable antibody titers despite active cerebral disease. Paired serology performed 2-4 weeks apart may demonstrate seroconversion. The utility of serology is enhanced when combined with other modalities. For a detailed discussion of ELISA methodology, refer to the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus (cross-applicable principles apply).

Cerebrospinal Fluid Analysis

Cerebrospinal fluid (CSF) collected from the cerebellomedullary cistern or lumbar subarachnoid space is essential for evaluation of CNS inflammation. Typical findings include moderate to marked mononuclear pleocytosis (50-500 cells/microliter), elevated protein concentration (50-300 mg/dL), and normal glucose levels. Eosinophilic pleocytosis is occasionally observed. Cytological examination may rarely reveal free tachyzoites, but sensitivity is low.

Molecular Detection (CSF PCR)

Polymerase chain reaction (PCR) targeting the B1 gene or the 529 bp repetitive element of T. gondii in CSF offers high specificity and moderate sensitivity. False negatives occur due to intermittent shedding of organisms, low parasite burden, or PCR inhibitors. Quantitative real-time PCR (qPCR) can provide an estimate of parasite load and may be useful for monitoring treatment response. CSF PCR is considered the most reliable antemortem test for confirming active cerebral toxoplasmosis and is highly recommended in any cat with neurological signs and positive serology.

Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) of the brain is increasingly used in veterinary neurology. In cerebral toxoplasmosis, MRI typically reveals solitary or multiple, T2-weighted hyperintense, contrast-enhancing lesions in the cerebral cortex, thalamus, or cerebellum. Lesions may exhibit ring enhancement or a target-like appearance with central necrosis. Edema and mass effect are common. MRI findings are suggestive but not pathognomonic; differential diagnoses include neoplasia (lymphoma, meningioma), granulomatous meningoencephalitis, and other infectious processes such as Feline Coronavirus and FIP or cryptococcosis.

Computed Tomography

Computed tomography (CT) is less sensitive than MRI for detecting cerebral toxoplasmosis but may show hypodense lesions with peripheral enhancement after contrast administration. It is more readily available in general practice but provides inferior soft tissue contrast.

Differential Diagnosis

Several CNS infections can mimic feline cerebral toxoplasmosis. The key differentials are listed in Table 2.

Table 2. Differential Diagnoses for Feline Cerebral Toxoplasmosis

The diagnostic workup should also include routine hematology, serum biochemistry (excluding infectious causes such as feline leukemia virus and feline coronavirus), and thoracic radiography to evaluate for concurrent systemic disease. A diagnostic algorithm is presented in the Mermaid diagram below.

flowchart TD
    A[Cat with neurological signs], > B{CSF PCR available?}
    B, >|Yes| C[Perform CSF PCR for T. gondii]
    C, > D{Positive?}
    D, >|Yes| E[Diagnosis: Cerebral toxoplasmosis]
    D, >|No| F[Perform MRI brain + CSF analysis]
    B, >|No| F
    F, > G[Lesions consistent with toxoplasmosis?]
    G, >|Yes| H[Serology IgM/IgG]
    H, > I{IgM+ or rising IgG?}
    I, >|Yes| E
    I, >|No| J[Consider other diagnoses]
    G, >|No| J
    J, > K[Test for FIP, Cryptococcus, lymphoma, etc.]

Treatment

Antimicrobial Therapy

Clindamycin is the first-line treatment for feline toxoplasmosis. It is administered at a dosage of 10-12 mg/kg orally or intramuscularly every 12 hours for 4-6 weeks. Clindamycin acts by binding to the 50S ribosomal subunit and inhibiting protein synthesis in tachyzoites. It has good CNS penetration, especially across inflamed meninges. Clinical improvement is often observed within 48-72 hours. Alternative or adjunctive therapies include trimethoprim-sulfonamide combinations (15 mg/kg every 12 hours) which inhibit tetrahydrofolate synthesis. Azithromycin (10 mg/kg every 24 hours) and pyrimethamine (0.5-1 mg/kg every 24 hours, combined with folic acid to prevent myelosuppression) are second-line options for refractory cases.

Treatment response should be monitored by serial neurological examinations. Repeat CSF PCR may be performed after 4 weeks to confirm clearance of organisms, although PCR can remain positive for some time after clinical resolution. Long-term suppressive therapy is not generally recommended for immunocompetent cats, but may be considered in cats with persistent immunosuppression (e.g., cats with concurrent Feline Leukemia Virus infection). Corticosteroids (e.g., prednisolone 0.5-1 mg/kg every 12 hours) are indicated only for severe cerebral edema or impending herniation, as they can exacerbate parasitemia.

Adjunctive and Supportive Care

Seizures should be managed with antiepileptic drugs such as phenobarbital (initial loading dose of 2-4 mg/kg intravenously, followed by 1-2 mg/kg every 12 hours orally) or levetiracetam (20 mg/kg every 8 hours). Fluid therapy and nutritional support are essential in anorexic cats. Ocular toxoplasmosis may require topical or systemic corticosteroids alongside antimicrobial therapy, under careful monitoring.

Prognosis

The prognosis for feline cerebral toxoplasmosis is guarded to fair, depending on the severity of neurological deficits and the presence of underlying immunosuppression. Cats that are diagnosed early and treated aggressively with clindamycin often show substantial improvement within 1-2 weeks. Severe cases with extensive brain necrosis, status epilepticus, or concurrent FeLV/FIV infection carry a poorer prognosis. Relapse can occur months to years later, particularly if the cat becomes immunosuppressed.

Conclusion

Feline toxoplasmosis with neurological involvement is an important differential in cats presenting with seizures, ataxia, or behavioral change. The pathogenesis involves both direct parasite-mediated injury and host inflammatory response. A definitive antemortem diagnosis requires a combination of serology, CSF PCR, and advanced imaging. Clindamycin remains the cornerstone of therapy, with adjunctive anticonvulsants and supportive care as needed. Clinicians should maintain a high index of suspicion for toxoplasmosis in cats with CNS signs, especially in those with concurrent retroviral infections, and differentiate it from other infectious and neoplastic conditions.

References

1. Dubey JP. Toxoplasmosis of Animals and Humans. 2nd ed. Boca Raton: CRC Press; 2010.
2. Lappin MR. Toxoplasmosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. St. Louis: Elsevier; 2012:806-826.
3. Dubey JP, Lappin MR. Toxoplasmosis and neosporosis. In: Sykes JE, ed. Canine and Feline Infectious Diseases. St. Louis: Elsevier; 2014:767-783.
4. Pfohl JC, Dewey CW. Cerebral toxoplasmosis in a cat. J Am Vet Med Assoc. 2005;226(8):1314-1317.
5. Gunn-Moore DA, Reed N. Toxoplasmosis in cats. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine. 7th ed. St. Louis: Saunders; 2010:1085-1090.